Temporal Regulation of the Bacterial Metabolite Deoxycholate during Colonic Repair Is Critical for Crypt Regeneration

Cell Host and Microbe

Volumn 24, Issue 3, 2018, Pages 353-363.e5

  Jain, Umang ^a   Lai, Chin Wen ^a   Xiong, Shanshan ^a   Goodwin, Victoria M ^a   Lu, Qiuhe ^a   Muegge, Brian D ^a   Christophi, George P ^a   VanDussen, Kelli L ^a   Cummings, Bethany P ^b   Young, Erick ^c   Hambor, John ^c   Stappenbeck, Thaddeus S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Cornell University ^*  (United States)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYCHOLIC ACID; FARNESOID X RECEPTOR; PROSTAGLANDIN E2; 15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; CYCLOOXYGENASE 2; N-(2-CYCLOHEXYLOXY-4-NITROPHENYL)METHANESULFONAMIDE; NITROBENZENE DERIVATIVE; PTGS2 PROTEIN, MOUSE; SULFONAMIDE; VANCOMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL REGENERATION; COLON; CONTROLLED STUDY; CRYPT CELL; FEMALE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; SIGNAL TRANSDUCTION; TISSUE REGENERATION; WOUND HEALING; ANIMAL; BACTERIUM; BIOPSY; INJURIES; INTESTINE FLORA; INTESTINE MUCOSA; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY; PRIMARY CELL CULTURE;

ANIMALS; BACTERIA; BIOPSY; COLON; CYCLOOXYGENASE 2; DEOXYCHOLIC ACID; DINOPROSTONE; GASTROINTESTINAL MICROBIOME; HYDROXYPROSTAGLANDIN DEHYDROGENASES; INTESTINAL MUCOSA; MICE; MICE, KNOCKOUT; NITROBENZENES; PRIMARY CELL CULTURE; SULFONAMIDES; VANCOMYCIN; WOUND HEALING;

EID: 85052980329     PISSN: 19313128     EISSN: 19346069     Source Type: Journal    
DOI: 10.1016/j.chom.2018.07.019     Document Type: Article

References (51)

1. Alam, A., Leoni, G., Wentworth, C.C., Kwal, J.M., Wu, H., Ardita, C.S., Swanson, P.A., Lambeth, J.D., Jones, R.M., Nusrat, A., Neish, A.S., Redox signaling regulates commensal-mediated mucosal homeostasis and restitution and requires formyl peptide receptor 1. Mucosal Immunol. 7 (2014), 645–655.
2. Alam, A., Leoni, G., Quiros, M., Wu, H., Desai, C., Nishio, H., Jones, R.M., Nusrat, A., Neish, A.S., The microenvironment of injured murine gut elicits a local pro-restitutive microbiota. Nat. Microbiol., 1, 2016, 15021.
3. Brown, S.L., Riehl, T.E., Walker, M.R., Geske, M.J., Doherty, J.M., Stenson, W.F., Stappenbeck, T.S., Myd88-dependent positioning of Ptgs2-expressing stromal cells maintains colonic epithelial proliferation during injury. J. Clin. Invest. 117 (2007), 258–269.
4. Buffie, C.G., Bucci, V., Stein, R.R., McKenney, P.T., Ling, L., Gobourne, A., No, D., Liu, H., Kinnebrew, M., Viale, A., et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517 (2015), 205–208.
5. Dehoux, P., Marvaud, J.C., Abouelleil, A., Earl, A.M., Lambert, T., Dauga, C., Comparative genomics of Clostridium bolteae and Clostridium clostridioforme reveals species-specific genomic properties and numerous putative antibiotic resistance determinants. BMC Genomics, 17, 2016, 819.
6. Donia, M.S., Fischbach, M.A., HUMAN MICROBIOTA. Small molecules from the human microbiota. Science, 349, 2015, 1254766.
7. Duboc, H., Rajca, S., Rainteau, D., Benarous, D., Maubert, M.A., Quervain, E., Thomas, G., Barbu, V., Humbert, L., Despras, G., et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut 62 (2013), 531–539.
8. Frank, D.N., St Amand, A.L., Feldman, R.A., Boedeker, E.C., Harpaz, N., Pace, N.R., Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl. Acad. Sci. USA 104 (2007), 13780–13785.
9. Gadaleta, R.M., van Erpecum, K.J., Oldenburg, B., Willemsen, E.C., Renooij, W., Murzilli, S., Klomp, L.W., Siersema, P.D., Schipper, M.E., Danese, S., et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 60 (2011), 463–472.
10. Geboes, K., Dalle, I., Influence of treatment on morphological features of mucosal inflammation. Gut 50:Suppl 3 (2002), III37–III42.
11. Gnewuch, C., Liebisch, G., Langmann, T., Dieplinger, B., Mueller, T., Haltmayer, M., Dieplinger, H., Zahn, A., Stremmel, W., Rogler, G., Schmitz, G., Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease. World J. Gastroenterol. 15 (2009), 3134–3141.
12. Kaiko, G.E., Ryu, S.H., Koues, O.I., Collins, P.L., Solnica-Krezel, L., Pearce, E.J., Pearce, E.L., Oltz, E.M., Stappenbeck, T.S., The Colonic Crypt Protects Stem Cells from Microbiota-Derived Metabolites. Cell 165 (2016), 1708–1720.
13. Komichi, D., Tazuma, S., Nishioka, T., Hyogo, H., Chayama, K., A nuclear receptor ligand down-regulates cytosolic phospholipase A2 expression to reduce bile acid-induced cyclooxygenase 2 activity in cholangiocytes: implications of anticarcinogenic action of farnesoid X receptor agonists. Dig. Dis. Sci. 50 (2005), 514–524.
14. Kruis, W., Kalek, H.D., Stellaard, F., Paumgartner, G., Altered fecal bile acid pattern in patients with inflammatory bowel disease. Digestion 35 (1986), 189–198.
15. Leoni, G., Alam, A., Neumann, P.A., Lambeth, J.D., Cheng, G., McCoy, J., Hilgarth, R.S., Kundu, K., Murthy, N., Kusters, D., et al. Annexin A1, formyl peptide receptor, and NOX1 orchestrate epithelial repair. J. Clin. Invest. 123 (2013), 443–454.
16. Leoni, G., Neumann, P.A., Kamaly, N., Quiros, M., Nishio, H., Jones, H.R., Sumagin, R., Hilgarth, R.S., Alam, A., Fredman, G., et al. Annexin A1-containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repair. J. Clin. Invest. 125 (2015), 1215–1227.
17. Leoni, G., Neumann, P.A., Sumagin, R., Denning, T.L., Nusrat, A., Wound repair: role of immune-epithelial interactions. Mucosal Immunol. 8 (2015), 959–968.
18. Lew, J.L., Zhao, A., Yu, J., Huang, L., De Pedro, N., Peláez, F., Wright, S.D., Cui, J., The farnesoid X receptor controls gene expression in a ligand- and promoter-selective fashion. J. Biol. Chem. 279 (2004), 8856–8861.
19. Manieri, N.A., Drylewicz, M.R., Miyoshi, H., Stappenbeck, T.S., Igf2bp1 is required for full induction of Ptgs2 mRNA in colonic mesenchymal stem cells in mice. Gastroenterology, 143, 2012 110–21.e10.
20. Martínez-Montiel, Mdel.P., Gómez-Gómez, G.J., Flores, A.I., Therapy with stem cells in inflammatory bowel disease. World J. Gastroenterol. 20 (2014), 1211–1227.
21. Masferrer, J.L., Zweifel, B.S., Manning, P.T., Hauser, S.D., Leahy, K.M., Smith, W.G., Isakson, P.C., Seibert, K., Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. USA 91 (1994), 3228–3232.
22. Matsumoto, M., Kibe, R., Ooga, T., Aiba, Y., Kurihara, S., Sawaki, E., Koga, Y., Benno, Y., Impact of intestinal microbiota on intestinal luminal metabolome. Sci. Rep., 2, 2012, 233.
23. Miyoshi, H., Ajima, R., Luo, C.T., Yamaguchi, T.P., Stappenbeck, T.S., Wnt5a potentiates TGF-β signaling to promote colonic crypt regeneration after tissue injury. Science 338 (2012), 108–113.
24. Miyoshi, H., VanDussen, K.L., Malvin, N.P., Ryu, S.H., Wang, Y., Sonnek, N.M., Lai, C.W., Stappenbeck, T.S., Prostaglandin E2 promotes intestinal repair through an adaptive cellular response of the epithelium. EMBO J. 36 (2017), 5–24.
25. Montrose, D.C., Nakanishi, M., Murphy, R.C., Zarini, S., McAleer, J.P., Vella, A.T., Rosenberg, D.W., The role of PGE2 in intestinal inflammation and tumorigenesis. Prostaglandins Other Lipid Mediat. 116-117 (2015), 26–36.
26. Morgan, X.C., Tickle, T.L., Sokol, H., Gevers, D., Devaney, K.L., Ward, D.V., Reyes, J.A., Shah, S.A., LeLeiko, N., Snapper, S.B., et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol., 13, 2012, R79.
27. Nava, G.M., Friedrichsen, H.J., Stappenbeck, T.S., Spatial organization of intestinal microbiota in the mouse ascending colon. ISME J. 5 (2011), 627–638.
28. Paiotti, A.P., Marchi, P., Miszputen, S.J., Oshima, C.T., Franco, M., Ribeiro, D.A., The role of nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors on experimental colitis. In Vivo 26 (2012), 381–393.
29. Parekkadan, B., Milwid, J.M., Mesenchymal stem cells as therapeutics. Annu. Rev. Biomed. Eng. 12 (2010), 87–117.
30. Park, J.Y., Pillinger, M.H., Abramson, S.B., Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clin. Immunol. 119 (2006), 229–240.
31. Pavlidis, P., Powell, N., Vincent, R.P., Ehrlich, D., Bjarnason, I., Hayee, B., Systematic review: bile acids and intestinal inflammation-luminal aggressors or regulators of mucosal defence?. Aliment. Pharmacol. Ther. 42 (2015), 802–817.
32. Rampton, D.S., Sladen, G.E., Youlten, L.J., Rectal mucosal prostaglandin E2 release and its relation to disease activity, electrical potential difference, and treatment in ulcerative colitis. Gut 21 (1980), 591–596.
33. Ridlon, J.M., Kang, D.J., Hylemon, P.B., Bile salt biotransformations by human intestinal bacteria. J. Lipid Res. 47 (2006), 241–259.
34. Sayin, S.I., Wahlström, A., Felin, J., Jäntti, S., Marschall, H.U., Bamberg, K., Angelin, B., Hyötyläinen, T., Orešič, M., Bäckhed, F., Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 17 (2013), 225–235.
35. Schaap, F.G., Trauner, M., Jansen, P.L., Bile acid receptors as targets for drug development. Nat. Rev. Gastroenterol. Hepatol. 11 (2014), 55–67.
36. Seno, H., Miyoshi, H., Brown, S.L., Geske, M.J., Colonna, M., Stappenbeck, T.S., Efficient colonic mucosal wound repair requires Trem2 signaling. Proc. Natl. Acad. Sci. USA 106 (2009), 256–261.
37. Steed, A.L., Christophi, G.P., Kaiko, G.E., Sun, L., Goodwin, V.M., Jain, U., Esaulova, E., Artyomov, M.N., Morales, D.J., Holtzman, M.J., et al. The microbial metabolite desaminotyrosine protects from influenza through type I interferon. Science 357 (2017), 498–502.
38. Studer, N., Desharnais, L., Beutler, M., Brugiroux, S., Terrazos, M.A., Menin, L., Schürch, C.M., McCoy, K.D., Kuehne, S.A., Minton, N.P., et al. Functional Intestinal Bile Acid 7α-Dehydroxylation by Clostridium scindens Associated with Protection from Clostridium difficile Infection in a Gnotobiotic Mouse Model. Front. Cell. Infect. Microbiol., 6, 2016, 191.
39. Sun, X., Winglee, K., Gharaibeh, R.Z., Gauthier, J., He, Z., Tripathi, P., Avram, D., Bruner, S., Fodor, A., Jobin, C., Microbiota-Derived Metabolic Factors Reduce Campylobacteriosis in Mice. Gastroenterology 154 (2018), 1751–1763.e2.
40. Turner, J.R., Intestinal mucosal barrier function in health and disease. Nat. Rev. Immunol. 9 (2009), 799–809.
41. Vavassori, P., Mencarelli, A., Renga, B., Distrutti, E., Fiorucci, S., The bile acid receptor FXR is a modulator of intestinal innate immunity. J. Immunol. 183 (2009), 6251–6261.
42. Voswinkel, J., Francois, S., Gorin, N.C., Chapel, A., Gastro-intestinal autoimmunity: preclinical experiences and successful therapy of fistulizing bowel diseases and gut Graft versus host disease by mesenchymal stromal cells. Immunol. Res. 56 (2013), 241–248.
43. Walker, M.R., Brown, S.L., Riehl, T.E., Stenson, W.F., Stappenbeck, T.S., Growth factor regulation of prostaglandin-endoperoxide synthase 2 (Ptgs2) expression in colonic mesenchymal stem cells. J. Biol. Chem. 285 (2010), 5026–5039.
44. Wang, H., Chen, J., Hollister, K., Sowers, L.C., Forman, B.M., Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell 3 (1999), 543–553.
45. Weingarden, A.R., Dosa, P.I., DeWinter, E., Steer, C.J., Shaughnessy, M.K., Johnson, J.R., Khoruts, A., Sadowsky, M.J., Changes in Colonic Bile Acid Composition following Fecal Microbiota Transplantation Are Sufficient to Control Clostridium difficile Germination and Growth. PLoS One, 11, 2016, e0147210.
46. Wells, J.E., Williams, K.B., Whitehead, T.R., Heuman, D.M., Hylemon, P.B., Development and application of a polymerase chain reaction assay for the detection and enumeration of bile acid 7alpha-dehydroxylating bacteria in human feces. Clin. Chim. Acta 331 (2003), 127–134.
47. Wiercinska-Drapalo, A., Flisiak, R., Prokopowicz, D., Mucosal and plasma prostaglandin E2 in ulcerative colitis. Hepatogastroenterology 46 (1999), 2338–2342.
48. Yoshimoto, S., Loo, T.M., Atarashi, K., Kanda, H., Sato, S., Oyadomari, S., Iwakura, Y., Oshima, K., Morita, H., Hattori, M., et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499 (2013), 97–101.
49. Yu, B.Z., Apitz-Castro, R.J., Jain, M.K., Berg, O.G., Role of 57-72 loop in the allosteric action of bile salts on pancreatic IB phospholipase A(2): regulation of fat and cholesterol homeostasis. Biochim. Biophys. Acta 1768 (2007), 2478–2490.
50. Yuli, S., Chengxu, L., Sydney M, F., Multiplex PCR for rapid differentiation of three species in the “Clostridium clostridioforme group”. FEMS Microbiol. Lett. 244 (2005), 391–395.
51. Zhang, Y., Desai, A., Yang, S.Y., Bae, K.B., Antczak, M.I., Fink, S.P., Tiwari, S., Willis, J.E., Williams, N.S., Dawson, D.M., et al. TISSUE REGENERATION. Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration. Science, 348, 2015, aaa2340.